Compliance — a driving force for influencing public perceptions of the pharma industry?
July 15, 2024 | Pharma, clinical trials, compliance, ethics
How does compliance play into public perceptions of pharma and why is it important for improving public opinion?
If you have anything to do with the pharma industry, we bet you’ll already know how important compliance is.
Supporting patients by providing them with the right information and tools to empower health is paramount, there’s no question of that. But it’s interesting to consider the role that compliance can play too. After all, it’s a way of making sure we’re always looking out for patients in an honest and transparent way.
So, it’s driving positive public perceptions right?
To some extent. But, despite compliance being necessary and an important pillar of our industry, it’s still sometimes considered to be a ‘box ticking exercise’ and dare we say it…just a bit boring.
There’s also often a bit of a compliance lockdown. By that, we mean the feeling that we can’t and shouldn’t talk about our industry’s amazing advances and scientific achievements because…well, is it compliant?
Which can leave the wider public feeling like the pharma world is a little mysterious.
A little mysterious?
Exactly that. We’ve even heard the pharma industry being described as…Batman!
Yes, none other than that powerful superhero who saves lives, and who is an overall force for good. But also, that same powerful superhero who is a bit of a distanced-masked-mysterious thing, lurking in the shadows. Not to mention, extremely wealthy.
And maybe it’s this juxtaposition that plays on minds, creating suspicions. Especially when it seems that much happens ‘undercover’.
But even those who are a bit more in the know have concerns. We understand that some HCPs are questioning how much pharma is actually driven by a desire to care for patients for example. Of course, we know this isn’t true. But it’s certainly becoming more obvious that there is a need for pharma to engage more with the public, support transparency where possible, and help right some of these more negative views. Could compliance help us do that?
But how?
Good question. Here are some thoughts from us on that very topic!
Start talking about the good of compliance to people inside and outside the industry.
- Explain how it gives the structure needed to do good work and make meaningful advances
- Challenge myths like ‘doing nothing is pretty much always compliant’ or ‘the riskier, the better for business’ to highlight how this flawed thinking impacts the people we’re trying to help
- Talk openly with the public about it to reassure how regulatory standards and ethical practices are prioritised
Make sure ethics drives compliance.
- Show the public commitment to corporate social responsibility, demonstrating that pharma isn’t profit-driven but cares about doing right
- Make patient-centricity core to your approach, making sure the good of the patient is the guiding principle right throughout the process of bringing a drug to market
Think about the 4 principles of medical ethics and apply as much or as many of them as possible.
- Beneficence: bring benefit to others
- Autonomy: respect the free will of others
- Non-maleficence: avoid harm to others
- Justice: be fair to others
Can we support you?
We put people at the heart of everything we do, so compliance is incredibly important to us. And since we work with our clients as an extension of their team, this is something that we regularly advise on.
From time to time, we hear concerns that compliance can be tricky to navigate when engaging with patients. We’re here to tell you that it doesn’t need to be the case.
In fact, patient engagement, partnerships, and co-creation are really what it’s all about; making sure we create solutions that are truly beneficial and meaningful.
This is why involving patients early on is core to our approach and way of working at Cuttsy+Cuttsy, and why we encourage embedding patients within the project process, assuming it’s the right thing for your project of course.
So, if you want a partner in crime to navigate the compliance storms, let’s talk.
References:
Beauchamp TL, Childress JF. Principles of biomedical ethics. 5th. New York: Oxford University Press; 2001.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Cuttsy+Cuttsy launches a practical roadmap to enhance clinical trial participant experience
Cuttsy+Cuttsy has launched The Experience Gap, a practical roadmap designed to help clinical trial teams improve participant engagement, support and retention across the full study journey.
Cuttsy+Cuttsy welcomes three new experts to the team
Cuttsy+Cuttsy is happy to be welcoming three new people to the team this month.
The gap between hype and reality, what patients really say about weight loss drugs
Explore real patient conversations about weight loss drugs, uncovering challenges, support strategies, and the critical need for clear, reliable healthcare communication.
Why patient-centricity depends on site-centricity in clinical trials
Explore why patient-centricity in clinical trials relies on site-centricity, emphasising the need to design trials that empower site teams to better support patients.
From cloudy to clear: visualising complex data privacy information
Discover how clear communication principles can transform complex clinical research topics, as we conclude our Health Literacy series with a practical example on participant data transparency.
UK clinical trial regs are changing — here’s what’s happening
Discover the transformative updates to UK clinical trial regulations, effective from April 2026, and learn how they aim to enhance transparency, participant safety, and trial efficiency.
The invisible influence on trial retention: why caregivers must be part of the plan
Caregivers are vital to clinical trial retention, yet often overlooked—this article highlights their challenges, impact, and how to better support them.
Where it all began: why we wrote ‘The Site Factor’
Discover the story behind ‘The Site Factor’ and how understanding site teams’ experiences can transform clinical trials for participants and researchers alike.
From text to context: Helping patients see side effects clearly
Discover how thoughtful design, clear language, and structured visuals can transform overwhelming side effect information into accessible, actionable insights for patients in our latest Health Literacy series.
Why patient engagement must come first in rare disease trials
Explore why patient engagement is the cornerstone of successful rare disease trials, emphasising the importance of designing studies around the realities of patients' lives to build trust and improve outcomes.